A cross-sectional study on the prevalence of cardiovascular disease in elderly patients with long-term type 2 diabetes mellitus mainly attended in private clinics in Mexico. The CAPTURE study
Background To estimate the contemporary prevalence of established cardiovascular disease (CVD) in adults with type 2 diabetes (T2D) in Mexico. Methods CAPTURE was a multinational, non-interventional, cross-sectional study across 13 countries from five continents. Standardized demographic and clinical data were collected from adults with T2D attending a single routine healthcare visit in primary or specialized care between December 2018 and September 2019. Data from Mexico are analyzed in this study. Results Of the 9,823 patients included in the CAPTURE study, 820 (8.3%) participants were from Mexico, mainly attended in private centers (29.3% in 6 specialized diabetes treatment centers and 70.7% in 26 primary care centers). The median age was 63.0 years, 52.6% were women, the duration of diabetes was 11.8 years and the average HbA1c 7.5%. The weighted prevalence [95% CI] of CVD and atherosclerotic CVD was 36.9% [34.1–39.6] and 29.5% [26.7–32.3], respectively. Additionally, the prevalence of coronary heart disease, heart failure, peripheral arterial disease and cerebrovascular disease was 23.1% [20.6–25-7], 8.4% [6.8–10.0], 5.0% [3.5–6.5] and 3.9% [2.6–5.2], respectively. Glucose lowering drugs were used in 88.5% of patients, being metformin the most commonly drug used (79.4%), followed by sulfonylureas (26.3%). SGLT-2 inhibitors and GLP1 receptor agonists were used in 15.5% and 3.9%, respectively. Conclusions In Mexico, nearly four out of ten patients with T2D mainly attended in private centers have CVD, particularly atherosclerotic CVD. Most patients were not taking glucose lowering drugs with proven CV benefit..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Diabetology & metabolic syndrome - 15(2023), 1 vom: 07. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arenas-León, José L. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s13098-023-01231-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054014999 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054014999 | ||
| 003 | DE-627 | ||
| 005 | 20231208064655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231208s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13098-023-01231-6 |2 doi | |
| 035 | |a (DE-627)SPR054014999 | ||
| 035 | |a (SPR)s13098-023-01231-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arenas-León, José L. |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A cross-sectional study on the prevalence of cardiovascular disease in elderly patients with long-term type 2 diabetes mellitus mainly attended in private clinics in Mexico. The CAPTURE study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background To estimate the contemporary prevalence of established cardiovascular disease (CVD) in adults with type 2 diabetes (T2D) in Mexico. Methods CAPTURE was a multinational, non-interventional, cross-sectional study across 13 countries from five continents. Standardized demographic and clinical data were collected from adults with T2D attending a single routine healthcare visit in primary or specialized care between December 2018 and September 2019. Data from Mexico are analyzed in this study. Results Of the 9,823 patients included in the CAPTURE study, 820 (8.3%) participants were from Mexico, mainly attended in private centers (29.3% in 6 specialized diabetes treatment centers and 70.7% in 26 primary care centers). The median age was 63.0 years, 52.6% were women, the duration of diabetes was 11.8 years and the average HbA1c 7.5%. The weighted prevalence [95% CI] of CVD and atherosclerotic CVD was 36.9% [34.1–39.6] and 29.5% [26.7–32.3], respectively. Additionally, the prevalence of coronary heart disease, heart failure, peripheral arterial disease and cerebrovascular disease was 23.1% [20.6–25-7], 8.4% [6.8–10.0], 5.0% [3.5–6.5] and 3.9% [2.6–5.2], respectively. Glucose lowering drugs were used in 88.5% of patients, being metformin the most commonly drug used (79.4%), followed by sulfonylureas (26.3%). SGLT-2 inhibitors and GLP1 receptor agonists were used in 15.5% and 3.9%, respectively. Conclusions In Mexico, nearly four out of ten patients with T2D mainly attended in private centers have CVD, particularly atherosclerotic CVD. Most patients were not taking glucose lowering drugs with proven CV benefit. | ||
| 650 | 4 | |a Atherosclerotic cardiovascular disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cardiovascular disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Aged |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Glucagon-like peptide-1 receptor agonists |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mexico |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Non-interventional study |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prevalence |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sodium-glucose co-transporter-2 inhibitors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Type 2 diabetes |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Morales-Villegas, Enrique C. |4 aut | |
| 700 | 1 | |a Cardona-Muñoz, Ernesto G. |4 aut | |
| 700 | 1 | |a Alcocer-Gamba, Marco A. |4 aut | |
| 700 | 1 | |a Ramirez-Contreras, Juan P. |4 aut | |
| 700 | 1 | |a Contreras-Sandoval, Aleida Y. |4 aut | |
| 700 | 1 | |a González-Galvez, Guillermo |0 (orcid)0000-0001-9611-2055 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetology & metabolic syndrome |d London : BioMed Central, 2009 |g 15(2023), 1 vom: 07. Dez. |w (DE-627)SPR030237963 |w (DE-600)2518786-7 |x 1758-5996 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:1 |g day:07 |g month:12 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13098-023-01231-6 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 1 |b 07 |c 12 | ||